Tom Kloetzly, sales and marketing VP for Shimadzu Medical Systems USA, explains the evolution of Shimadzu Corporation since its founding 142 years ago. Kloetzly focuses on the Trinias Interventional X-ray line shown at RSNA 2016. Kloetzly states “A key feature of Trinias, is the ability to image from fingertip to fingertip during a transradial approach which makes for much shorter hospital stay with the patient up and moving almost immediately after the procedure. Features Like RSM-DSA, a type of motion correction subtraction, eliminates patient movement during acquisition while STENTVIEW, is an enhanced visualization during stent placement in real-time." For more information: www.shimadzu.com/med/products/angio/index.html.

A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit. He presented a late-breaking study on the outcomes for 15,259 U.S. patients with acute MI in cardiogenic shock supported with the Impella percutenous ventricular assist device. Read more about the Detroit Cardiogenic Shock Initiative.

Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses the two year outcomes of the ABSORB III trial of Absorb vs. Xience. The late-breaking trial was presented at ACC 2017. Read the article on the ABSORB III results.  Watch a VIDEO with Gregg Stone, M.D., "Poor Outcomes for Bioresorbable Stents in Small Coronary Arteries."

Michael Reardon, M.D., professor of cardiothoracic surgery at Houston Methodist DeBakey Heart and Vascular Center, discusses the positive results of the SURTAVI trial that were presented at ACC.17. Reardon was the principal investigator for the SURTAVI trial. Read the article "TAVR Stands Equal to Surgical Valve Replacement." 

This video, provided by Abiomed, demonstrates the Impella percutaneous ventricular assist devices (pVAD). It offers between 2.5 and 5 liters of flow per minute to help off load the heart and aid organ perfusion in patients with significantly compromised cardiac output. The Impella has an FDA indication for cardiogenic shock and is the key device being used in the Detroit Cardiogenic Shock Initiative, which was launched in 2017. Read the article "Collaboration by Metro Detroit Cardiologists Increases Cardiogenic Shock Survival Rate."

ITN Editor Dave Fornell takes a tour of some of the most innovative new technology that was displayed on the expo floor at the 2017 Healthcare Information and Management Systems Society (HIMSS) annual meeting. The two most significant technology advances are discussed in Fornell's blog "Two Technologies That Offer a Paradigm Shift in Medicine at HIMSS 2017."

The supplies you use in your cath lab are complex and very valuable. Protecting your investment and uncovering new opportunities to cut waste and help improve the total cost of care means it’s more important than ever before to have a strong pulse on your inventory. Using data analytics, you can uncover trends for product standardization, optimize par levels and better control costs.

This video, provided by BioVentrix Inc., demonstrates how to implant the Revivent TC System to reduce the volume of the left ventricle (LV) in heart failure patients. Reducing the size of the LV can help make pumping more efficient, helping to reduce the workload of a failing heart. It is a minimally invasive, catheter-based, closed-chest alternative to conventional surgical ventricular restoration (SVR). It uses catheter-deployed anchors designed to exclude scarred myocardial tissue from the LV to help restore its more natural conical shape. Read about the system gaining European approval.  Read about system starting its U.S. clinical trial. 

ITN and DAIC Editor Dave Fornell takes a tour of some of the most innovative new technologies being displayed on the expo floor at the Radiological Society of North America (RSNA) 2016 meeting. For key take away trends at RSNA, watch the video "Key Trends, New Technology at RSNA 2016."

Mahadevappa Mahesh, MS, Ph.D., chief physicist and professor of radiology and radiological science at Johns Hopkins Hospital, explains the basics of medical imaging dose monitoring technologies. This includes monitoring and recording software meet new Joint Commission requirements, state dose laws and to improve patient safety regarding X-ray radiation exposure. Read the article “The Role of Dose Tracking Systems in Radiation Safety Programs.”

Corindus Vascular Robotics received U.S. Food and Drug Administration (FDA) 510(k) clearance for its CorPath GRX, the second generation of its vascular robotic system. The system builds upon the original CorPath platform, adding a significant number of key upgrades that increase precision, improve workflow and extend the capabilities and range of interventional procedures that can be performed robotically. These features include Active Guide Management, which enables control of the guide catheter along with robotic control of the guidewire and balloon or stent catheter, with 1 millimeter advancement, from the Control Console. This precise positioning will enable physicians to adjust guide catheter position during PCI procedures, and may expand use of CorPath to more complex cases. The new system also features a completely redesigned Bedside Unit, featuring an Extended Reach Arm and a touchscreen display to streamline workflow.

The CorPath GRX was displayed for the first time at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 conference. Read more about the FDA approval.

A discussion with Torsten Vahl, M.D., about advancements in transcatheter valve repair technology, including new devices for the aortic, mitral and tricuspid valves.  Vahl is director of experimental and translational research and assistant professor of medicine, Columbia University Medical Center, Center for Interventional Vascular Therapy. The interview took place at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 annual meeting.

Watch an updated 2019 interview with Vahl in the VIDEO: The Expansion of TAVR Following the FDA Clearing its Use in All Patients.

Related Transcatheter Valve Content:

Advances and Future Directions for Transcatheter Valves

Transcatheter Mitral Valve Replacement Devices in Development

Advances in Transcatheter Tricuspid Valve Technologies

VIDEO: Update of Mitral Valve Repair and Replacement Technologies at TCT 2017 — Interview with Ted Feldman, M.D.,

TAVR Operator and Hospital Requirements Outlined in 2018 AATS/ACC/SCAI/STS Expert Consensus

VIDEO: Tricuspid Device Clinical Trial Overview — Interview with Ori Ben-Yehuda, M.D.

Recent Advances in Transcatheter Valve Technology

VIDEO: Tricuspid Valve Imaging and Interventions Developing Hand-in-hand at ASE 2018— Interview with Rebecca Hahn, M.D.

Hospital Consolidation May Increase Access to TAVR, New Cardiac Technologies

VIDEO: TAVR for Degenerated Surgical Valves - 2017 Update— Valve-in-Valve TAVR Procedures — Interview with Sammy Elmariah, M.D.

How to Perform Transcaval TAVR Access

VIDEO: The Essentials of CT Transcatheter Valve Imaging — Interview with Jonathon Leipsic, M.D.

Advances in Heart Valve Technology in 2017

VIDEO: TAVR For Asymptomatic Severe Aortic Stenosis — Interview with Philippe Genereux, M.D.

VIDEO: Conscious Sedation for TAVR Procedures — Interview with Mario Goessl, M.D.

VIDEO: Overview of the Henry Ford Hospital Structural Heart Program

A discussion with Juan Granada, M.D., about transcatheter mitral valve advancements and device challenges at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 annual meeting. Granada is executive director and chief scientific officer of the Cardiovascular Research Foundation's Skirball Center for Innovation. There is a big movement toward transcatheter interventions for the mitral valve after the major success of and rapid expansion of transcatheter aortic valve replacement (TAVR) technology. However, he said the mitral valve anatomy is much more complex and it is not as simple as using a TAVR valve in the mitral position. 

Related TMVR Content:

VIDEO: Transcatheter Mitral Valve Replacement Planning — Interview with Joao Cavalcante, M.D.

Advances and Future Directions for Transcatheter Valves

Transcatheter Mitral Valve Replacement Devices in Development

Interventional Imagers: The Conductors of the Heart Team Orchestra

VIDEO: The Importance of the Neo-LVOT in Transcatheter Mitral Valve Replacement  — Interview with Dee Dee Wang, M.D.

VIDEO: Transcatheter Structural Heart Procedure Navigation Technology Advances  — Interview with Stephen Little, M.D.

Recent Advances in Transcatheter Valve Technology

Abbott Begins Tendyne Transcatheter Mitral Valve U.S. Pivotal Trial

VIDEO: The Essentials of CT Transcatheter Valve Imaging — Interview with Jonathon Leipsic, M.D.,

New LAMPOON Technique Reduces LVOT Obstruction in Transcatheter Mitral Valve Replacement

A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 annual meeting. Brinton is clinical associate professor and adjunct associate professor of bioengineering at Stanford University Medical Center. Read the article “FDA Clears Lithoplasty Balloon That Shatters Calcified Lesions With Ultrasound.”
 

A discussion with Michael Reardon, M.D. about the state of transcatheter aortic valve replacement (TAVR) as of late 2016. He is a professor of cardiothoracic surgery at Houston Methodist DeBakey Heart and Vascular Center, was the chairman of the patient screening committee for the CoreValve U.S. pivotal trial, nation PI on the Lotus Pivotal Trial, and the national PI of the ongoing the CoreValve intermediate and low-risk trials. Read more in the article "Trends in Transcatheter Aortic Valve Replacement (TAVR)."

Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance of building a good heart team and how that team should interact. They gave a presentation on image guidance for structural heart procedures at TCT 2016, but focused repeatedly on the need for close collaboration to be successful. Read more in the article "Requirements for Interventional Echocardiographers."

David Kandzari, M.D., director of interventional cardiology and chief scientific officer, Piedmont Heart Institute, Atlanta, Ga., explains the impact of the EXCEL Trial at TCT 2016. Piedmont recruited the highest number of patients for the large, randomized trial found the Xience V drug-eluting stent had comparable outcomes to coronary artery bypass graft surgery. This is the first time this parity has been shown in a large trial. Read the article "Stents, Bypass Surgery Equally Safe and Effective for Many With Left Main Heart Disease."

Read the article - Left Main Treated With PCI or CABG Have Similar Outcomes at Five Years — EXCEL 5-year Data at TCT 2019

This video, provided by Zoll, demonstrates how cardiologists can explain sudden cardiac death to patients. It is critical to educate patients who are at risk of sudden cardiac arrest (SCA), so Rahul Doshi, M.D., director of electrophysiology, associate professor of clinical medicine, Keck Medical Center of University of Southern California, explains sudden cardiac death (SCD) to his patients using a simple illustration. Visit SCDFacts.org for additional resources for you and your team to support the SCD conversation with your patients. One in five post-AMI patients have been shown to be at high risk of dying after PCI.1 The majority of mortality in AMI patients post-PCI occurs in the first three months — one out of every 10 high-risk patients die, with about 60 percent of this mortality due to SCD.[1,2] 

1. Halkin A, et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: CADILLAC Risk Score. JACC 2005;45:1397–1405.

2. Stone G, et al. Prevention of Sudden Cardiac Arrest Post PTCA in High-Risk Patients. Medscape. April 2011. https://www.medscape.org/viewarticle/741503_transcript

With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient care, there is no room in your cath lab for high-value medical device waste. An automated inventory management solution could help you find and reduce the waste hiding in your supply chain while helping to improve your total cost of care. Visit cardinalhealth.com/CIMS. 

Pacemakers, stents and bandages — keeping tracking of what is on hand and accurately capturing charges can be a challenge. What if you could track, manage and analyze your cath lab inventory – low cost to high value – to reveal powerful business intelligence and shine a light on new savings and revenue capture?